Matthew Zibelman
@MattZibelman
Followers
339
Following
2K
Media
25
Statuses
367
RT @LauraBukavinaMD: New pub alert 🚨 The bladder microbiome may influence intravesical chemotherapy response in bladder cancer. 🦠💊. 🧪 we te….
0
19
0
RT @FoxChaseCancer: Daniel Geynisman discusses the RETAIN-1 trial, exploring bladder preservation strategies in muscle-invasive bladder can….
0
1
0
RT @FoxChaseCancer: Can bladder cancer patients safely avoid surgery? @FoxChaseCancer’s INSITE trial, led by Drs. Kutikov (@uretericbud) &….
foxchase.org
Susan Rux (center) is Principal Investigator on a study aiming to diversify participatio
0
2
0
RT @GazzoniGabriela: New in @UrolOncol ✨. We evaluated EV-related skin reactions in 2,500 UC pts. 🔹50% of all-grade SR and 20% SCAR. 🔹Most….
0
3
0
Great and exciting innovative work by @TiansterZhang Can’t wait to learn about next steps.
@andyzwang @DrChoueiri @neerajaiims @montypal @PGrivasMDPhD @ERPlimackMD @KidneyCancer @kcCURE @kidneycan @utswcancer @UTSWHemeOnc @UTSW_RadOnc @ndesai2005 @ithinkichan @UTSWInternalMed @MalladiLab @JBrugarolas Supported by @DOD #KCRP Idea Development Award. We are grateful for the funding & the chance to make a difference for our patients w/ #kidneycancer. For more details please see our paper #MolecularCancer @BioMedCentral. #FIN
0
0
2
RT @jitcancer: New #JITC article: Development and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for str….
0
7
0
RT @ERPlimackMD: Proud of our @FoxChaseCancer fellow #JoeVanGalen on his @ConquerCancerFd #ASCO25 YIA investigating novel approaches to ir….
0
9
0
RT @DrJZell: Just finished a “Great Debate” on ctDNA as MRD in CRC with some tough competition from stellar oncologist @NVijayvergiaMD & mo….
0
2
0
Can We Save the Bladder in MIBC? RETAIN-2 Shows Hope! .A study testing chemo + immunotherapy (AMVAC + nivolumab) in muscle-invasive bladder cancer (MIBC) shows promising results. #GU25 #cancer #oncology #BladderCancer @shilpaonc @asco @oncoalert @MikeSerzanMD @drenriquegrande
0
0
1
⏩ @ASCO #GU25:.Risk-adapted chemoimmunotherapy (NAC + nivolumab) approach shows promising bladder preservation & MFS in MIBC!.✅ Key Findings:. 🔹 46% pT0 rate in pts undergoing RC. 🔹 78% MFS with bladder preservation in active surveillance group.@yekeduz_emre
0
3
10
RT @yasserged: Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatme….
journals.lww.com
KI combinations remains unclear. We conducted a retrospective analysis of IO combinations in mtRCC patients at 4 institutions. Eligible patients had confirmed mtRCC by genitourinary pathologist and...
0
12
0
RT @FoxChaseCancer: If you have or have had kidney cancer, and/or are interested in learning more about clinical trials for kidney cancer,….
0
1
0
RT @OncoAlert: Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) Out in J….
0
16
0
Please join us for this event discussing what we do best: optimizing treatment for our patients with GU malignancies.
Join us on 11/20 for an in-person CME tackling challenges in treating complex genitourinary cancer cases. Covering the latest in surgical techniques, radiation therapies, & treatments for localized & advanced bladder, kidney, & prostate cancers. Register:
0
1
8
RT @uretericbud: Thank you for this incredible honor of the Andrew C. Novick Award. Immensely humbled by this recognition from the @KidneyC….
0
9
0
RT @FoxChaseCancer: Researchers at Fox Chase just published the results of a phase 1 study that showed reduced immune-related side effects….
0
5
0
RT @TA_Urology: 💉Immunotherapy for castration-resistant #prostatecancer?. CAR T-cells and BiTEs targeting PSMA may just be the future. 🔥An….
0
3
0
RT @urotoday: Survival outcomes in patients with muscle-invasive #BladderCancer receiving neoadjuvant chemotherapy stratified by the number….
0
9
0
Happening now. @BenMironMD @FCUroOnc @FoxChaseCancer educating us about real world data and relevance to #RCC #ASCO2023
1
1
12
RT @efratdotan: @NVijayvergiaMD putting PROs into context for patients with hepatobilliary tumors, and the importance of patient's centered….
0
6
0